Advice
Following a full submission.
Ibandronic acid is accepted for use within NHS Scotland for the treatment of tumour-induced hypercalcaemia with or without metastases.
It has been shown to be a cost-effective option in reducing serum calcium in patients with hypercalcaemia of malignancy.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Ibandronic acid (Bondronat®)
- SMC ID:
- 122/04
- Indication:
- Tumour-induced hypercalcaemia with or without metastases
- Pharmaceutical company
- Roche
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 October 2004